Yeji
NDA/BLA filedoutcome: unknownconf 0.95

defencath — NDA/BLA filed

$CRMD · CorMedix Inc.
Event date
March 28, 2022
1531 days ago
Sponsor runway
cash-flow +
$178.1M liquid

Evidence

the resubmission of the New Drug Application for DefenCath has been accepted for filing by the U.S. Food and Drug Administration.
Source: 8-K filed 2022-03-28View on EDGAR ↗0001213900-22-015306

Comparable historical nda/bla fileds· last 5 years · same event type

TickerDrugDateOutcome
$AXSM2025-12-31unknown
$RCKTkresladi2025-10-14unknown
$ALDXreproxalap2025-07-17unknown
$ETONet-6002025-07-08unknown
$BCRXorladeyo (berotralstat)2025-05-14unknown
$CORTrelacorilant2025-03-03unknown
$ALDXreproxalap2024-11-01unknown
$AXSMaxs-072024-09-04unknown
$RCKTkresladi2023-10-02unknown
$GERNimetelstat2023-08-21unknown

Recent insider activity· ±90 days

11 insiders · 2 buys · 0 sells
Buy
2022-05-17
Kaplan Myron
Director
5,000 @ $3.78$19K
Buy
2022-05-16
Todisco Joseph
Chief Executive Officer
10,000 @ $3.38$34K
Grant
2022-05-10
Todisco Joseph
Chief Executive Officer
500,000 @
Grant
2022-05-10
Todisco Joseph
Chief Executive Officer
207,469 @
Grant
2022-02-22
Costa Paulo F
Director
20,000 @
Grant
2022-02-22
Duncan Gregory Scott
Director
20,000 @
Grant
2022-02-22
Lefkowitz Steven W
Director
20,000 @
Grant
2022-02-22
DUNTON ALAN W
Director
20,000 @
Grant
2022-02-22
Dillione Janet
Director
20,000 @
Grant
2022-02-22
Kaplan Myron
Director
20,000 @
Grant
2022-02-18
David Matthew T
Chief Financial Officer
@
Grant
2022-02-18
Hurlburt Elizabeth
Chief Operating Officer
100,000 @
Grant
2022-02-18
Nusbickel Thomas
EVP, Chief Commercial Officer
100,000 @
Grant
2022-02-18
Mounts Phoebe
General Counsel
140,000 @